



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

13<sup>th</sup> May 2025

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Subject: Media release: Q4 of 2024-25**

Please find enclosed a press release issued by the Company in respect to financial results for the quarter & year ended 31<sup>st</sup> March 2025.

This is for your information and record.

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151



## **GlaxoSmithKline Pharmaceuticals Limited Reports Topline Growth and Profitability for Full Year Ended 31 March 2025**

**Board of Directors of the Company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025**

**Mumbai, Maharashtra – May 13, 2025 – GlaxoSmithKline (GSK) Pharmaceuticals Limited today announced its financial results for the fourth quarter and full year ended March 31, 2025.**

The company reported full year revenue of Rs. 3723 crores, a growth of 9%. Profit After Tax before exceptional items increased by 32% to Rs. 915 crores and EBITDA margins increased by 500 basis points (bps) to 31.4%.

For the quarter ended March 31, 2025, the company reported a revenue of Rs. 966 crores, a like-to-like growth of 6%. Profit After Tax for the quarter stood at Rs.260 crores.

Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.”

“We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,” he added.

The company is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer.

## **About GlaxoSmithKline Pharmaceuticals Limited (GSK)**

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit [GSK-India.com](http://GSK-India.com).

For further information, please contact:

### **Communications & Government Affairs**

Carson Dalton  
[carson.a.dalton@gsk.com](mailto:carson.a.dalton@gsk.com)

Farah Bookwala  
[farah.a.bookwala@gsk.com](mailto:farah.a.bookwala@gsk.com)

\*\*\*\*